Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTP001 in Idiopathic Pulmonary Fibrosis
2023-508729-28-00Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing LTP001 with Placebo to LTP001 (2 arms). Primary endpoint: Change from baseline to end of treatment epoch in forced vital capacity (percent predicted). Started Mar 2024; status: completed.
02
Drugs
LTP001
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2023-508729-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508729-28-00.